Ingredient

Lactobacillus rhamnosus GG (LGG)

Ingredient information and published studies.

Find products
Share

Email article

Published

Lactobacillus rhamnosus GG, or LGG, is a bacterial strain first isolated from the stool of a healthy adult. Since a 2020 reclassification, its species has been called Lacticaseibacillus rhamnosus. Its culture collection number is ATCC 53103. Supplements sell it alone or with other strains and count it in colony-forming units (CFU).

Terms and sources
first isolated
Segers and Lebeer, Microb Cell Fact, 2014. The letters GG come from the surnames of the two researchers who isolated it.
2020 reclassification
Zheng et al., Int J Syst Evol Microbiol, 2020, split the genus Lactobacillus into 25 genera. PubMed now indexes the species under the new name.
ATCC 53103
ATCC: American Type Culture Collection. Segers and Lebeer, 2014.
colony-forming units (CFU)
NIH ODS: "The number of viable cells in a probiotic supplement is indicated by the number of colony-forming units (CFU) listed on the label."

LGG in the body

LGG is a live bacterium, not a nutrient, and the body has no daily requirement for it. Trials of LGG in healthy adults measure things such as its survival in stool and blood markers.

NIH ODS writes: "The International Scientific Association for Probiotics and Prebiotics defines probiotics as ‘live microorganisms that, when administered in adequate amounts, confer a health benefit on the host.’" It adds: "However, not all foods and dietary supplements that are labeled as probiotics have proven health benefits." NIH ODS notes: "Probiotics are identified by their genus, species, and strain designation; some probiotics also receive subspecies names." It adds: "Probiotic products often contain microbial organisms from the genera Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus, Escherichia, and Bacillus and from the family Lactobacillaceae." In this name, rhamnosus is the species and GG the strain. NCCIH notes: "The most common are bacteria that belong to groups called Lactobacillus and Bifidobacterium." It adds: "Different types of probiotics may have different effects."

Terms and sources
NIH ODS writes
From the International Scientific Association for Probiotics and Prebiotics, 2014, as quoted by NIH ODS.
NIH ODS notes
The whole NIH ODS paragraph under "Identification", in two sentences. NIH Office of Dietary Supplements, fact sheet for health professionals.
NCCIH notes
National Center for Complementary and Integrative Health, Probiotics: Usefulness and Safety.

The genome of LGG is about 3.0 million base pairs long. It carries 80 genes, in 5 genomic islands, that the related strain LC705 lacks. One island holds genes for pili whose SpaC protein binds human intestinal mucus. Kankainen and colleagues write that SpaC likely explains why LGG persisted in the gut longer than LC705 in a trial.

Terms and sources
3.0 million base pairs
Kankainen et al., PNAS, 2009, compared it with a closely related strain, L. rhamnosus LC705.
pili
Adhesive pili, or fimbriae, on the cell surface (Segers and Lebeer, 2014). Without a working spaC gene, LGG did not bind mucus in the lab. Kankainen et al., 2009.

NIH ODS notes: "Probiotics are unlikely to cause harm in healthy people, and side effects are usually minor." It continues: "However, the use of probiotics has been linked to a few cases of bacteremia, fungemia, and infections that have resulted in severe illness; most of these cases involved individuals who were severely ill or immunocompromised." NCCIH says: "Probiotics have an extensive history of apparently safe use, particularly in healthy people." It continues: "However, few studies have looked at the safety of probiotics in detail, so there’s a lack of solid information on the frequency and severity of side effects." NCCIH adds: "The risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems." It continues: "When probiotics are being considered for high-risk individuals, such as premature infants or seriously ill hospital patients, the potential risks of probiotics should be carefully weighed against their benefits." NCCIH notes: "Cases of severe or fatal infections have been reported in premature infants who were given probiotics, and the U.S. Food and Drug Administration (FDA) has warned health care providers about this risk." It adds: "Possible harmful effects of probiotics include infections, production of harmful substances by the probiotic microorganisms, and transfer of antibiotic resistance genes from probiotic microorganisms to other microorganisms in the digestive tract." NCCIH also says: "Some probiotic products have been reported to contain microorganisms other than those listed on the label." It continues: "In some instances, these contaminants may pose serious health risks." NCCIH advises: "Don’t use probiotics as a reason to postpone seeing your health care provider about any health problem." It adds: "If you’re considering a probiotic dietary supplement, consult your health care provider first." It continues: "This is especially important if you have health problems." And: "Anyone with a serious underlying health condition should be monitored closely while taking probiotics."

Terms and sources
NIH ODS notes
The first paragraph of the Safety Considerations section of the NIH ODS probiotics fact sheet for health professionals. The rest of the section describes case reports and hospital data, including LGG given to people in intensive care.
It continues
Bacteremia and fungemia: bacteria or fungi in the blood (our explanation).
NCCIH says
The whole section, in four paragraphs, as NCCIH wrote it. Then two of the three points under "More To Consider".

Where LGG comes from

Its source sample was the stool of a healthy adult, according to Segers and Lebeer. It was picked for resistance to acid and bile, good growth and adhesion to the gut lining. A 2019 review states that LGG was the first Lactobacillus strain to be patented, in 1989.

Terms and sources
Segers and Lebeer
Microb Cell Fact, 2014.
adhesion to the gut lining
To the intestinal epithelial layer, in the words of Segers and Lebeer, 2014.
A 2019 review
Capurso, J Clin Gastroenterol, 2019. Single author; we could not read the conflict section.

In one trial, the product was freeze-dried LGG made by Chr. Hansen A/S. The studies below gave it in capsules, microcapsules, a milk drink, fermented milk or a spread.

Terms and sources
freeze-dried LGG
Bornholdt et al., Gut Microbes, 2020. Not shown below: volunteers had a gut procedure under sedation.
capsules, microcapsules
Capsules: Saxelin 1995. Microcapsules: Saiz-Gonzalo 2026. Milk-based drink: Kekkonen 2008. Fermented milk: Trachootham 2021. Spread: Dommels 2009.

NIH ODS notes: "Some types of fermented foods, such as yogurt, are potential sources of beneficial microbes, though not all fermented foods that contain live cultures have probiotic microorganisms." It adds: "Probiotic microorganisms are also sometimes added to unfermented foods."

Terms and sources
NIH ODS notes
The whole NIH ODS paragraph under "Food", in two sentences.

Daily amounts and the upper limit

NIH ODS notes: "There are currently no formal recommendations for or against the use of probiotics in healthy people." It adds: "However, some expert bodies of health professionals provide guidance on the use of specific probiotic strains in people with certain health conditions." It continues: "These groups also offer guidance for clinicians and consumers on choosing probiotic products."

Terms and sources
NIH ODS notes
The first paragraph of the NIH ODS section "Probiotic Selection and Use".

United States

There is no US recommended daily amount for LGG. The National Academies have not set an upper limit for LGG.

NCCIH notes: "Government regulation of probiotics in the United States is complex." It adds: "Depending on a probiotic product’s intended use, the FDA might regulate it as a dietary supplement, a food ingredient, or a drug."

Terms and sources
NCCIH notes
National Center for Complementary and Integrative Health, Probiotics: Usefulness and Safety.

In the NIH label database, 524 US labels name LGG in an ingredient or form entry. Another 3,405 labels name Lactobacillus rhamnosus without the GG strain. Of the 524, 390 also name other microbes, and 134 name no other microbe.

Terms and sources
524 US labels
NIH Dietary Supplement Label Database, 214,768 labels, including products no longer sold. Whole-word search for rhamnosus GG, Lactobacillus GG, LGG or ATCC 53103 within one entry; LGG in capitals only. We counted these.
3,405 labels
These labels are not counted below. Many name another strain, such as LR-32, HN001 or GR-1. We counted these.
390 also name other microbes
Other bacteria or yeasts named in any entry of the label. We counted these.

On 480 of the 524 labels, the LGG entry has no amount of its own. Of the 134 labels with no other microbe, 74 give a count in billions in the label text. Of the 134, 43 also list inulin.

Terms and sources
480 of the 524
On 387 of the 390 labels with other microbes, the LGG entry has no amount of its own. Of the 44 labels with an amount, 41 give mg.
74 give a count in billions
10 billion on 41 labels, 6 of which also give 20 billion. 15 billion on 19 labels, 5 or 20 billion on 5 each. Labels word the count as live cultures, cells or CFU. We counted these.
43 also list inulin
NIH ODS lists inulin among carbohydrates "that microorganisms in the gastrointestinal tract use as metabolic fuel."

Forms of LGG and how they differ

NIH ODS notes: "Dietary supplements that contain probiotics can include from one to many strains." It adds: "The number of viable cells in a probiotic supplement is indicated by the number of colony-forming units (CFU) listed on the label." It continues: "However, it can be difficult to determine which products offer verifiable health benefits due to the wide variety of probiotic strains and doses found in probiotic products and inconsistent labeling practices and recommendations for use." Products with LGG and other strains were not tested in the studies below. We do not rank forms.

Terms and sources
NIH ODS notes
The whole NIH ODS paragraph under "Dietary supplements", in three sentences.
LGG capsules, drinks, a spread, microencapsulated LGG and blends with other strains
FormWhat it isStudies below
CapsulesLGG in gelatin capsulesStool: Saxelin 1995.
Drinks and fermented milkLGG in a milk-based drink, or milk fermented with LGGImmune markers: Kekkonen 2008. Acetaldehyde: Trachootham 2021.
SpreadLGG in a low-fat spreadStool lactobacilli: Dommels 2009.
Microencapsulated LGGLGG in microcapsules, as the trial report calls itBlood serotonin: Saiz-Gonzalo 2026.
Blends with other strainsProducts that also name other bacteria or yeastsNot in the studies below.
Lactobacillus rhamnosus without GGThe species named without GG or ATCC 53103Not in the studies below.

Capsules: Saxelin 1995. Drinks: Kekkonen 2008 and Trachootham 2021. Spread: Dommels 2009. Microencapsulated LGG: Saiz-Gonzalo 2026. Blends: NIH ODS on strains.

Published studies of LGG

Many trials of LGG enrolled children, people with a diagnosis or people taking antibiotics. Those trials, trials of blends and trials that counted illness episodes are not listed here.

5 studies in adults not chosen for a diagnosis: 3 found a difference, 1 none. 1 measured LGG in stool.

Not listed: trials in people taking antibiotics, and a review of such trials in children and adults. Also not listed: trials in which everyone also got a vaccine. Also not listed: trials that counted illness episodes. Also not listed: a trial in women chosen for bowel complaints. Also not listed: studies with gut samples taken by endoscopy under sedation or by colon biopsy. Also not listed: studies without a dummy group or with one group only, one chosen by stress scores. Also not listed: a trial that compares each group only with its own start. Also not listed: a study in which some volunteers also took an antibiotic. Also not listed: products with added fiber, and a trial whose dummy snack had less fiber. Also not listed: a combined analysis that includes blends. Also not listed: trials in which some participants took medicines. Also not listed: other reports of trials shown here.

Our one-line summary comes first. The original is on PubMed.

Show the 5 studies
  • Adults took an LGG milk drink for 3 weeks; cultured blood cells released less TNF-alpha than with a dummy drink.

    Trial · 62 people in 4 groups: 13 LGG, 16 dummy drink, 16 and 17 other strains · 3 weeks · industry co-funded

    Kekkonen et al., World J Gastroenterol, 2008

    Terms and sources
    Adults
    62 healthy adults aged 23 to 58. They were randomized to LGG, one of two other bacterial strains, or a dummy drink. Another report of this trial: some blood lipid classes changed in the LGG group from the start. A third report found no significant change in stool proteins with LGG compared with the dummy drink.
    LGG milk drink
    250 mL a day of a milk-based fruit drink with 16 billion CFU of LGG.
    TNF-alpha
    A signal protein of the immune system, released by blood cells grown in the lab. The difference was statistically significant. The 4 groups also differed in blood CRP, a marker of inflammation (p = 0.014). In pairwise tests, LGG differed from one other strain, not from the dummy drink.
    a dummy drink
    Placebo drink without added bacteria.
    industry co-funded
    The article names the Academy of Finland and Valio Research Centre as funders. Another report of this trial lists the first author at Valio Oy.

    Study · Free full text · about 23 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    Sixty-two healthy adults aged 23 to 58 drank 250 mL of a milk-based fruit drink a day for 3 weeks. It held 16 billion CFU of LGG, one of two other bacterial strains, or no added bacteria. Researchers grew blood cells from each person in the lab. TNF-alpha, a signal protein of the immune system, was lower in the LGG group than in the dummy group. The four groups differed in blood CRP, a marker of inflammation. In pairwise tests, LGG differed from one other strain, not from the dummy drink. Funding: the Academy of Finland and Valio Research Centre.

  • Adults ate a spread with LGG for 3 weeks; stool lactobacilli rose more than with a dummy spread.

    Trial · 47 randomized to 3 groups; 42 analyzed: 16 LGG, 13 dummy spread, 13 another strain · 3 weeks · maker-supplied

    Dommels et al., Appl Environ Microbiol, 2009

    Terms and sources
    Adults
    Healthy adults aged 18 to 55 in the Netherlands; average age in the groups was 42 to 45. 47 were randomized; 42 were analyzed, 16 of them with LGG. A third group ate a spread with another strain, L. reuteri DSM 17938.
    a spread with LGG
    20 g of low-fat spread a day. The target was at least 5 billion CFU of LGG. Measured counts were 33 to 56 billion CFU per 20 g. The LGG strain came from Valio, per the paper.
    stool lactobacilli rose more
    Total live lactobacilli in stool, against the dummy group: statistically significant (one-sided test). After 3 weeks, LGG grew from the stool of all 16 in the LGG group. DNA tests found it in 15 of 16. The LGG counts are compared with the start only.
    a dummy spread
    Placebo spread. Adverse events: 3 with LGG, 4 with the dummy spread; none were judged related to the spreads.
    maker-supplied
    Unilever produced and supplied the spreads, and the study took place at its research institute. The first author works at Unilever R&D. The article has no funding section.

    Study · Free full text · about 28 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    Healthy adults aged 18 to 55 ate 20 g a day of a low-fat spread for 3 weeks. It held LGG, another strain, or no added bacteria. The LGG spread held 33 to 56 billion CFU per 20 g, as measured. Live lactobacilli in stool rose more with the LGG spread than with the dummy spread. After 3 weeks, LGG grew from the stool of all 16 people in the LGG group. The LGG counts were compared only with the start. Adverse events were few in all groups. Funding: Unilever made and supplied the spreads.

  • Adults took microencapsulated LGG for 28 days; blood serotonin did not differ from a dummy product.

    Trial · 21 people · 28 days · maker-supplied

    Saiz-Gonzalo et al., Sleep Advances, 2026

    Terms and sources
    Adults
    21 healthy adults, average age 30; 13 took LGG and 8 the dummy product. Six reported 5 hours of sleep a night or less.
    microencapsulated LGG
    10 billion CFU a day, as stated in the paper.
    blood serotonin
    Fasting serotonin in blood at the start and on day 28. Women had higher values than men. The LGG group started with higher values. The authors call the trial small and exploratory.
    a dummy product
    Placebo: matching maltodextrin, 5 g a day.
    maker-supplied
    AnaBio Technologies developed and provided the LGG microcapsules and the dummy product, the paper states. Three of 5 authors work at AnaBio. The paper states that no external funding was received. Another author reports grants from AnaBio, among other funders.

    Study · Free full text · about 13 min to read

    Our estimate at about 200 words a minute, from the full text without tables.

    Study summary

    Twenty-one healthy adults, average age 30, took microencapsulated LGG or a dummy product for 28 days. Thirteen took LGG and 8 the dummy product. Six people reported 5 hours of sleep a night or less. Fasting blood serotonin did not differ between LGG and the dummy product. Women had higher serotonin than men. The LGG group started with higher values. The authors call the trial small and exploratory. Funding: AnaBio Technologies, where 3 of 5 authors work, developed and provided the LGG and dummy product.

  • Men drank milk fermented with LGG before beer; blood acetaldehyde was lower than with dummy milk.

    Trial · 20 people · Two single doses, 1 week apart

    Trachootham et al., Food Funct, 2021

    Terms and sources
    Men
    20 healthy Thai men: 10 with the usual ALDH2 gene and 10 with one copy of a variant. The authors note that acetaldehyde builds up more with the variant.
    milk fermented with LGG
    150 mL, then five glasses of beer (0.4 g of alcohol per kg of body weight). Each man had both milks in random order, 1 week apart. The milk held 100 million CFU of LGG per mL, about 15 billion CFU in all by our estimate.
    blood acetaldehyde
    Acetaldehyde is a breakdown product of alcohol. It was lower in blood and in saliva over the hours after drinking. The differences were statistically significant. LGG stayed in saliva for at least 3.5 hours. Flushing lasted a shorter time; the abstract gives no significance test for it.
    dummy milk
    Placebo: lactic-acidified milk. The report calls it blinded; PubMed indexes it as single-blind.

    Study · Abstract only · about 2 min to read

    Our estimate from the abstract, at about 200 words a minute.

    Study summary

    Twenty healthy Thai men drank 150 mL of milk fermented with LGG or acidified milk as a dummy. Then they drank five glasses of beer. Each man did both, one week apart, in random order. Half carried one copy of a variant of the ALDH2 gene. Acetaldehyde, a breakdown product of alcohol, was lower in blood and saliva after LGG milk. Flushing lasted a shorter time. The abstract gives no significance test for flushing. LGG stayed in saliva for at least 3.5 hours. Funding: Europe PMC lists Mahidol University and Thailand Science Research and Innovation as funders.

  • Volunteers took LGG capsules for 7 days; at the higher dose, all had LGG in their stool.

    Study · 20 people · 7 days · industry author

    Saxelin et al., Int J Food Microbiol, 1995

    Terms and sources
    Volunteers
    20 healthy volunteers. The abstract does not say how they were split between the two doses.
    LGG capsules
    Gelatin capsules with 160 million or 12 billion CFU a day.
    all had LGG in their stool
    The abstract also states that the strain was found in the stool of all volunteers after 3 days. Total stool lactobacilli did not change. There was no dummy group.
    industry author
    The first author works at Valio Ltd, R&D, by PubMed. We could not read the article.

    Study · Abstract only · about 2 min to read

    Our estimate from the abstract, at about 200 words a minute.

    Study summary

    Twenty healthy volunteers took gelatin capsules with LGG for 7 days, at 160 million or 12 billion CFU a day. Researchers looked for the strain in stool. At the higher dose, all volunteers had LGG in their stool during the test week. The abstract also states that all volunteers had the strain in their stool after 3 days. Total stool lactobacilli did not change. There was no dummy group. Funding: we could not read the article; the first author works at Valio Ltd.

Sources

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.

Find products

Search the catalogue for Lactobacillus rhamnosus GG (LGG)

Not sure what to choose, or couldn’t find what you were looking for? Ask our expert

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own. If you have a health condition, are pregnant or breastfeeding, take medicines, or are under 18, talk to a doctor or pharmacist first.